Evommune News Releases

Jun 29, 2026 8:30 am EDT

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

May 7, 2026 4:05 pm EDT

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Apr 6, 2026 9:00 am EDT

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Mar 5, 2026 4:01 pm EST

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Feb 12, 2026 8:30 pm EST

Evommune Announces $125 Million Private Placement

Feb 10, 2026 7:30 am EST

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Dec 11, 2025 4:05 pm EST

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025 4:05 pm EST

Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 5, 2025 7:45 pm EST

Evommune Announces Pricing of its Initial Public Offering

Oct 30, 2025 6:30 am EDT

Evommune Announces Commencement of Initial Public Offering